Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on February 5, 2014, covering events occurring on January 30, 2014. The registrant is a Delaware corporation headquartered in Annapolis, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Executive Departure: On January 30, 2014, the Company terminated Jordan P. Karp, Esq., who served as Senior Vice President and General Counsel.
- Position Elimination: The Company eliminated the position of General Counsel entirely.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the specific personnel change reported.
Investor Verification Checklist
- Confirm the strategic rationale for eliminating the General Counsel position.
- Verify if legal responsibilities have been reassigned to other officers or external counsel.
- Check for any subsequent filings regarding the appointment of a new legal lead or interim counsel.